BEST OF ONCOLOGY WEST 2024: Prostate Cancer – Dr. Nimira Alimohamed

Studies/trials discussed:

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
ARASENS Study Design
PROPEL Study Design: ASCO GU 2022: PROpel: Phase III Trial of Olaparib and Abiraterone Versus Placebo and Abiraterone as First-Line Therapy for Patients with mCRPC
MAGNITUDE: ESMO 2023: MAGNITUDE Three-Year Update and Final Analysis: Niraparib with Abiraterone Acetate plus Prednisone as First-Line Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alteration
ASCO GU 2023: Niraparib with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Homologous Recombination Repair Gene Alterations: Second Interim Analysis of MAGNITUDE
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)